CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER: NDA 19777/S12

CHEMISTRY REVIEW(S)

CHEMIST'S REVIEW	1. ORGANIZATION HFD-110	2. NDA Number 19-777
3. Name and Address of Applicant (City & State) ICI Pharmaceuticals Group Wilmington, DE 19897		4. Supplement(s) Number(s) Date(s) S-012 10/8/91
5. Drug Name Zestril	6. Nonproprietary Name Lisinopril	7. Amendments & Other (reports, etc) - Dates amend 12/2/91
8. Supplement Provides For: The contract manufacture of two intermediates used for the synthesis of lisinopril.		
9. Pharmacological Category Antihypertensive	10. How Dispensed [X] Rx [ ] OTC	11. Related IND(s)/ NDA(s)/DMF(s) NDA 19-558 Prinivil, Merck
12. Dosage Form(s) TCM	13. Potency(ies) 5, 10, 20, 40 mg	
14. Chemical Name and Structure		15. Records/Reports Current [X] Yes [ ] No Reviewed [X] Yes [ ] No

16. Comments:

The supplement provides a new source(s) for the starting materials, TFA-lysine and ethyl benzoylacrylate. The methods of preparation of these two substances remain the same, but will purchase these substances rather than synthesize them.

Attachment 1 contains a copy of the Agency's letter approving S-008 which provides for the synthesis of TFA-lisinopril ester by

17. Conclusions and Recommendations:

APPROVAL is recommended for this supplement.

18. REVIEWER

Name James H.Short /S/ Date Completed 12/6/91

Distribution: [■] Original Jacket [ ] Reviewer [ ] Division File [ ] CSO

jhs/10/29/91/N19-777.S12

R/D init.: RWolters/12/10/91

12-11-91